Hovione announces successful end-of-phase 2 meeting with the FDA and outlines phase 3 program for minocycline topical gel

Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea.

Hovione Announces the Appointment of Jean-Luc Herbeaux as Chief Operating Officer

Effective May 1st, 2020

Bilim Pharmaceuticals, H&T Presspart and Hovione Technology unveil collaboration for new asthma product: Ventofor Combi Fix delivered by PowdAir Plus

Hovione Announces Partnership to Support Manufacturing of Antiviral Veklury® for COVID-19

Hovione today announced the signing of a partnership agreement with Ligand to significantly ramp up the production output of Captisol®

Hovione Launches ASD-HIPROS

The Most Advanced Screening Service for Optimal Spray Dried Dispersions Formulation

Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic

Showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction

Hovione and iBET announce strategic collaboration

A strategic partnership that will take Hovione to new technology frontiers.

Hovione invests $170 million in new capacity and capabilities

Hovione, the global leader in spray drying and particle engineering, today announced that it is expanding its industrial facilities around the world to support its ambitious growth objectives

Hovione announces New Pharma Campus expansion in New Jersey

This expansion in New Jersey will create up to 100 jobs over the next few years is part of a global expansion strategy

Hovione increases prices for its off-patent Active Pharmaceutical Ingredients, Portfolio Products as well as Development and Manufacturing Services

News release, 18 February 2022